STRENGTHS AND LIMITATIONS OF THIS STUDY
The study followed a standardised approach throughout all steps of this methodological study according to a prospectively registered protocol and study selection, data extraction and assessments were performed independently by two reviewers.
Methodological quality, reporting quality and several facets of transparency, including trial registration, results posting, and protocol, analytic code and data availability, were assessed.
Risk of bias, completeness of reporting and transparency were assessed using standardised instruments, such as the revised Cochrane risk-of-bias tool (RoB 2) and a checklist based on the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement and its extension for abstracts.
The 10 most-cited eligible trials per year from 2018 to 2022 were identified based on citation rank.
All assessments were based on publicly accessible sources without contacting trial authors, so that risk-of-bias judgements and evaluation of reporting and transparency reflect…
This post was originally published on https://bmjopen.bmj.com